Barclays Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Barclays analyst Luke Sergott upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $310 to $400.